Matthew J. Hlinka
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Articles
Recent Developments in Patent Law: Non-Obviousness of Chemical and Pharmaceutical Patents
USA - August 26 2020 Join a discussion on recent developments in patent law, particularly the non-obviousness of chemical and pharmaceutical patents. During the…
Recent Developments in Patent Law: Non-Obviousness of Pharmaceutical Formulations
USA - August 29 2019 The development of pharmaceutical products is often expensive and unpredictable. Researchers investing the time and resources to develop a novel and…
FDA Draft Guidance on Submitting Documents Using Real-World Data and Real-World Evidence
USA - May 17 2019 On May 8, 2019, FDA issued draft guidance for the submission of documents using real-world data (RWD) and real-world evidence (RWE) to FDA for drugs…
FDA Final Guidance on Application of Statutory Factors in Determining When a REMS is Necessary
USA - April 11 2019 On April 4, 2019, FDA issued final guidance on FDA’s application of the statutory factors in determining when a risk evaluation and mitigation…
The Internet of Things: Divided Infringement
USA - November 10 2016 Some analysts predict the Internet of Things (IoT) market will grow from nearly $2 trillion in 2013 to $7 trillion in 2020. With this rapid growth…
